GENINUS Inc. (KOSDAQ:389030)

South Korea · Delayed Price · Currency is KRW

2,450.00

+155.00 (6.75%)

At close: Jun 30, 2026

11.36% (1Y)

Market Cap	96.51B +24.7%
Revenue (ttm)	10.24B +39.8%
Net Income	-17.03B
EPS	-510.40
Shares Out	39.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,774,747
Open	2,385.00
Previous Close	2,295.00
Day's Range	2,340.00 - 2,980.00
52-Week Range	1,490.00 - 6,480.00
Beta	0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About GENINUS

GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia. It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It serves hospitals, pharmaceutical companies, and researchers. The company was founded in 2018 and is headquartered in Seoul, South Korea. [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2018

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 389030

Full Company Profile

Financial Performance

In 2025, GENINUS's revenue was 10.48 billion, an increase of 62.40% compared to the previous year's 6.46 billion. Losses were -17.37 billion, 41.6% more than in 2024.

Financial Statements